1. Home
  2. WORX vs ENTO Comparison

WORX vs ENTO Comparison

Compare WORX & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WORX
  • ENTO
  • Stock Information
  • Founded
  • WORX N/A
  • ENTO 2014
  • Country
  • WORX United States
  • ENTO United States
  • Employees
  • WORX N/A
  • ENTO N/A
  • Industry
  • WORX Services-Misc. Amusement & Recreation
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • WORX Consumer Discretionary
  • ENTO Health Care
  • Exchange
  • WORX Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • WORX 2.5M
  • ENTO 2.3M
  • IPO Year
  • WORX N/A
  • ENTO 2016
  • Fundamental
  • Price
  • WORX $0.31
  • ENTO $3.59
  • Analyst Decision
  • WORX
  • ENTO
  • Analyst Count
  • WORX 0
  • ENTO 0
  • Target Price
  • WORX N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • WORX 8.1M
  • ENTO 171.3K
  • Earning Date
  • WORX 11-13-2025
  • ENTO 11-12-2025
  • Dividend Yield
  • WORX N/A
  • ENTO N/A
  • EPS Growth
  • WORX N/A
  • ENTO N/A
  • EPS
  • WORX N/A
  • ENTO N/A
  • Revenue
  • WORX $2,838,404.00
  • ENTO N/A
  • Revenue This Year
  • WORX N/A
  • ENTO N/A
  • Revenue Next Year
  • WORX N/A
  • ENTO N/A
  • P/E Ratio
  • WORX N/A
  • ENTO N/A
  • Revenue Growth
  • WORX N/A
  • ENTO N/A
  • 52 Week Low
  • WORX $0.26
  • ENTO $0.92
  • 52 Week High
  • WORX $3.31
  • ENTO $3.70
  • Technical
  • Relative Strength Index (RSI)
  • WORX 46.51
  • ENTO 74.18
  • Support Level
  • WORX $0.28
  • ENTO $2.25
  • Resistance Level
  • WORX $0.32
  • ENTO $2.95
  • Average True Range (ATR)
  • WORX 0.05
  • ENTO 0.37
  • MACD
  • WORX 0.00
  • ENTO 0.07
  • Stochastic Oscillator
  • WORX 8.81
  • ENTO 94.42

About WORX SCWorx Corp.

SCWorx Corp is a provider of data content and services related to the repair, normalization, and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. Its software enables a healthcare provider to simplify and organize its data, allows the data to be utilized across multiple internal software applications, and provides the basis for sophisticated data analytics. The company has developed and markets healthcare information technology solutions and associated services to improve healthcare processes and information flow within hospitals and other healthcare facilities.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: